ArticleDigestive diseases and sciences2009
Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma.
Article in Digestive diseases and sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Understanding the role of hypoxia inducible factors in liver fibrosis and future therapeutic applications.iLIVER · 2026Review
- P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC.Journal of molecular histology · 2023Article
- Review
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.The Journal of clinical investigation · 2019Article
- Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.Oxidative medicine and cellular longevity · 2019Article
- Investigating Effect of Rapamycin and Metformin on Angiogenesis in Hepatocellular Carcinoma Cell Line.Advanced pharmaceutical bulletin · 2018Article
- Hypoxia as a target for drug combination therapy of liver cancer.Anti-cancer drugs · 2017Article
- Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Meta gene · 2015Article
- Future therapies of wet age-related macular degeneration.Journal of ophthalmology · 2015Review
- Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.Current drug targets · 2013Review
- Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.Clinical & experimental metastasis · 2013Article
- The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin.Molecular biology reports · 2012Article
- Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.Lasers in surgery and medicine · 2012Article
- Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression.Inflammation · 2012Article
- Hypoxia and hypoxia inducible factors: diverse roles in liver diseases.Hepatology (Baltimore, Md.) · 2012Review
- Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.Cellular and molecular life sciences : CMLS · 2012Review
- Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.Hepatology (Baltimore, Md.) · 2010Article
- Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.Journal of oncology · 2010Article
- Article
- H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.Molecular cancer research : MCR · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapamycin (RAPA) inhibits tumor growth and angiogenesis in hepatocellular carcinoma (HCC). The molecular mechanism underlying the antitumoral effects of RAPA remains unclear. Here we established a chemical-induced rat HCC model to investigate the signaling pathways mediating RAPA's antitumor activity. We found that RAPA exposure significantly diminished tumor growth, angiogenesis, and metastasis of HCC. Meanwhile, the antitumor drug dramatically decreased expression of HIF-1alpha and VEGF, either at mRNA or protein levels. Moreover, the low-dose of RAPA (1.5 mg/kg/day) was effective enough to markedly inhibit tumor progression of HCC. The preliminary results suggested that the antitumoral effects of RAPA might be at least partially mediated through downregulation of HIF-1alpha and VEGF, and low-dose RAPA-based regimens exhibited a promising future in treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.